{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:11:57Z","timestamp":1792012317817,"version":"4.4.0"},"reference-count":41,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,5,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Patients with core-binding factor (CBF) acute myeloid leukemia (AML), caused by either t(8;21)(q22;q22) or inv(16)(p13q22)\/t(16;16)(p13;q22), have higher complete remission rates and longer survival than patients with other subtypes of AML. However, \u223c40% of patients relapse, and the literature suggests that patients with inv(16) fare differently from those with t(8;21). We retrospectively analyzed 537 patients with CBF-AML, focusing on additional cytogenetic aberrations to examine their impact on clinical outcomes. Trisomies of chromosomes 8, 21, or 22 were significantly more common in patients with inv(16)\/t(16;16): 16% vs 7%, 6% vs 0%, and 17% vs 0%, respectively. In contrast, del(9q) and loss of a sex chromosome were more frequent in patients with t(8;21): 15% vs 0.4% for del(9q), 37% vs 0% for loss of X in females, and 44% vs 5% for loss of Y in males. Hyperdiploidy was more frequent in patients with inv(16) (25% vs 9%, whereas hypodiploidy was more frequent in patients with t(8;21) (37% vs 3%. In multivariable analyses (adjusted for age, white blood counts at diagnosis, and KIT mutation status), trisomy 8 was associated with improved overall survival (OS) in inv(16), whereas the presence of other chromosomal abnormalities (not trisomy 8) was associated with decreased OS. In patients with t(8;21), hypodiploidy was associated with improved disease-free survival; hyperdiploidy and del(9q) were associated with improved OS. KIT mutation (either positive or not tested, compared with negative) conferred poor prognoses in univariate analysis only in patients with t(8;21).<\/jats:p>","DOI":"10.1182\/bloodadvances.2020003605","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T15:33:13Z","timestamp":1621351993000},"page":"2481-2489","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":46,"title":["Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)"],"prefix":"10.1182","volume":"5","author":[{"given":"Se young","family":"Han","sequence":"first","affiliation":[{"name":"Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Mr\u00f3zek","sequence":"additional","affiliation":[{"name":"Clara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Voutsinas","sequence":"additional","affiliation":[{"name":"Clinical Biostatistics, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wu","sequence":"additional","affiliation":[{"name":"Clinical Biostatistics, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5880-9337","authenticated-orcid":false,"given":"Elizabeth A.","family":"Morgan","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9354-8221","authenticated-orcid":false,"given":"Hanne","family":"Vestergaard","sequence":"additional","affiliation":[{"name":"Mastocytosis Center and"},{"name":"Department of Hematology, Odense University Hospital, Odense, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Ohgami","sequence":"additional","affiliation":[{"name":"Department of Pathology, Stanford University, Stanford, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip M.","family":"Kluin","sequence":"additional","affiliation":[{"name":"Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Kielsgaard","family":"Kristensen","sequence":"additional","affiliation":[{"name":"Mastocytosis Center and"},{"name":"Department of Pathology, Odense University Hospital, Odense, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheeja","family":"Pullarkat","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of California, Los Angeles, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2041-3630","authenticated-orcid":false,"given":"Michael Boe","family":"M\u00f8ller","sequence":"additional","affiliation":[{"name":"Mastocytosis Center and"},{"name":"Department of Pathology, Odense University Hospital, Odense, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3555-8672","authenticated-orcid":false,"given":"Ana-Iris","family":"Schiefer","sequence":"additional","affiliation":[{"name":"Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda B.","family":"Baughn","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic, Rochester, MN;"},{"name":"Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pathology, City of Hope National Medical Center, Duarte, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Czuchlewski","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of New Mexico, Albuquerque, NM;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3726-8935","authenticated-orcid":false,"given":"Jacobien R.","family":"Hilberink","sequence":"additional","affiliation":[{"name":"Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Horny","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Ludwig-Maximilian University, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy I.","family":"George","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of New Mexico, Albuquerque, NM;"},{"name":"Department of Pathology, University of Utah, Salt Lake City, UT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Dolan","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam K.","family":"Ku","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of California, Los Angeles, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5420-3514","authenticated-orcid":false,"given":"Cecilia","family":"Arana Yi","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of New Mexico, Albuquerque, NM;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Pullarkat","sequence":"additional","affiliation":[{"name":"Division of Hematology and HCT, City of Hope National Medical Center, Duarte, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Kohlschmidt","sequence":"additional","affiliation":[{"name":"Clara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandeep","family":"Salhotra","sequence":"additional","affiliation":[{"name":"Division of Hematology and HCT, City of Hope National Medical Center, Duarte, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Soma","sequence":"additional","affiliation":[{"name":"Clinical Reseach Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara D.","family":"Bloomfield","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, The Ohio State University, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang R.","family":"Sperr","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hemostaseology, Department of Internal Medicine I, and"},{"name":"Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Marcucci","sequence":"additional","affiliation":[{"name":"Division of Hematology and HCT, City of Hope National Medical Center, Duarte, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Cho","sequence":"additional","affiliation":[{"name":"Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Medicine, Weill Cornell Medical College; New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Akin","sequence":"additional","affiliation":[{"name":"Division of Allergy and Clinical Immunology, University of Michigan, Ann Arbor, Michigan, MI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigurd","family":"Broesby-Olsen","sequence":"additional","affiliation":[{"name":"Mastocytosis Center and"},{"name":"Department of Dermatology and Allergy Centre, Odense Research Center for Anaphylaxis, Odense, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Larson","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology and Cell Therapy, Rush University, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Linden","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4426-9023","authenticated-orcid":false,"given":"H. Joachim","family":"Deeg","sequence":"additional","affiliation":[{"name":"Clinical Reseach Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Hoermann","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria;"},{"name":"Central Institute of Medical and Chemical Laboratory Diagnostics, University Hospital Innsbruck, Innsbruck, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[{"name":"Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Medicine, Weill Cornell Medical College; New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason L.","family":"Hornick","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9816-6302","authenticated-orcid":false,"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and"},{"name":"Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9082-0680","authenticated-orcid":false,"given":"Ryotaro","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Division of Hematology and HCT, City of Hope National Medical Center, Duarte, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8078-8579","authenticated-orcid":false,"given":"Daniel","family":"Weisdorf","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerwin","family":"Huls","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0456-5095","authenticated-orcid":false,"given":"Peter","family":"Valent","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hemostaseology, Department of Internal Medicine I, and"},{"name":"Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6896-6213","authenticated-orcid":false,"given":"Celalettin","family":"Ustun","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN;"},{"name":"Division of Hematology, Oncology and Cell Therapy, Rush University, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6799-2022","authenticated-orcid":false,"given":"Cecilia C. S.","family":"Yeung","sequence":"additional","affiliation":[{"name":"Clinical Reseach Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,5,18]]},"reference":[{"issue":"12","key":"2021051815330396800_B1","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3324\/haematol.2012.066100","article-title":"Survival for older patients with acute myeloid leukemia: a population-based study","volume":"97","author":"Oran","year":"2012","journal-title":"Haematologica"},{"issue":"36","key":"2021051815330396800_B2","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1200\/JCO.2012.43.4738","article-title":"Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia","volume":"30","author":"Mr\u00f3zek","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"2021051815330396800_B3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/CCO.0b013e32831369df","article-title":"Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia","volume":"20","author":"Mr\u00f3zek","year":"2008","journal-title":"Curr Opin Oncol"},{"issue":"2","key":"2021051815330396800_B4","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1006\/geno.1994.1519","article-title":"AML1, AML2, and AML3, the human members of the runt domain gene-family: cDNA structure, expression, and chromosomal localization","volume":"23","author":"Levanon","year":"1994","journal-title":"Genomics"},{"issue":"3","key":"2021051815330396800_B5","first-page":"809","article-title":"Isolation of PEBP2 alpha B cDNA representing the mouse homolog of human acute myeloid leukemia gene, AML1","volume":"8","author":"Bae","year":"1993","journal-title":"Oncogene"},{"issue":"12","key":"2021051815330396800_B6","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/ajh.23821","article-title":"Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy","volume":"89","author":"Solh","year":"2014","journal-title":"Am J Hematol"},{"issue":"4","key":"2021051815330396800_B7","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2021051815330396800_B8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.seminhematol.2015.04.002","article-title":"Core binding factor acute myeloid leukemia: New prognostic categories and therapeutic opportunities","volume":"52","author":"Sinha","year":"2015","journal-title":"Semin Hematol"},{"issue":"2","key":"2021051815330396800_B9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2006.06276.x","article-title":"The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations","volume":"135","author":"Appelbaum","year":"2006","journal-title":"Br J Haematol"},{"issue":"7","key":"2021051815330396800_B10","doi-asserted-by":"crossref","first-page":"926","DOI":"10.6004\/jnccn.2017.0116","article-title":"Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology","volume":"15","author":"O\u2019Donnell","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"2021051815330396800_B11","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/blood-2012-05-431486","article-title":"Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG)","volume":"121","author":"Paschka","year":"2013","journal-title":"Blood"},{"issue":"12","key":"2021051815330396800_B12","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2012-10-462879","article-title":"Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia","volume":"121","author":"Jourdan","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2021051815330396800_B13","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1182\/blood-2006-10-049783","article-title":"Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia","volume":"110","author":"Bullinger","year":"2007","journal-title":"Blood"},{"issue":"6","key":"2021051815330396800_B14","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/ajh.24000","article-title":"Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up","volume":"90","author":"Mosna","year":"2015","journal-title":"Am J Hematol"},{"issue":"20","key":"2021051815330396800_B15","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood-2015-12-688705","article-title":"Comprehensive mutational profiling of core binding factor acute myeloid leukemia","volume":"127","author":"Duployez","year":"2016","journal-title":"Blood"},{"issue":"12","key":"2021051815330396800_B16","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2021051815330396800_B17","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1038\/ng.3709","article-title":"The genomic landscape of core-binding factor acute myeloid leukemias","volume":"48","author":"Faber","year":"2016","journal-title":"Nat Genet"},{"issue":"6","key":"2021051815330396800_B18","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1365-2141.2006.06229.x","article-title":"Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)\/AML1-ETO","volume":"134","author":"Kuchenbauer","year":"2006","journal-title":"Br J Haematol"},{"issue":"24","key":"2021051815330396800_B19","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1200\/JCO.2005.15.610","article-title":"Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study","volume":"23","author":"Marcucci","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"2021051815330396800_B20","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1080\/10428194.2019.1709836","article-title":"Loss of X chromosome predicts favorable prognosis in female patients with t(8;21) acute myeloid leukemia","volume":"61","author":"Chen","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"18","key":"2021051815330396800_B21","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.2004.03.012","article-title":"Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup","volume":"22","author":"Schlenk","year":"2004","journal-title":"J Clin Oncol"},{"issue":"4","key":"2021051815330396800_B22","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1080\/10428194.2019.1683734","article-title":"Loss of the Y chromosome predicts a high relapse risk in younger adult male patients with t(8;21) acute myeloid leukemia on high-dose cytarabine consolidation therapy: a retrospective multicenter study","volume":"61","author":"Zhou","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"24","key":"2021051815330396800_B23","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1182\/bloodadvances.2020002673","article-title":"Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication","volume":"4","author":"Jahn","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"2021051815330396800_B24","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/ajh.25814","article-title":"Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study","volume":"95","author":"Rogers","year":"2020","journal-title":"Am J Hematol"},{"issue":"1","key":"2021051815330396800_B25","doi-asserted-by":"crossref","first-page":"e386","DOI":"10.1038\/bcj.2015.114","article-title":"Karyotype complexity and prognosis in acute myeloid leukemia","volume":"6","author":"St\u00f6lzel","year":"2016","journal-title":"Blood Cancer J"},{"issue":"13","key":"2021051815330396800_B26","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1182\/blood-2002-03-0772","article-title":"Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)","volume":"100","author":"Byrd","year":"2002","journal-title":"Blood"},{"issue":"7382","key":"2021051815330396800_B27","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature10738","article-title":"Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"issue":"9","key":"2021051815330396800_B28","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1182\/blood-2005-09-3640","article-title":"Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study","volume":"107","author":"Cairoli","year":"2006","journal-title":"Blood"},{"issue":"5","key":"2021051815330396800_B29","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1182\/blood-2005-04-1466","article-title":"KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival","volume":"107","author":"Schnittger","year":"2006","journal-title":"Blood"},{"issue":"24","key":"2021051815330396800_B30","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1200\/JCO.2006.06.9500","article-title":"Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study","volume":"24","author":"Paschka","year":"2006","journal-title":"J Clin Oncol"},{"issue":"12","key":"2021051815330396800_B31","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N Engl J Med"},{"key":"2021051815330396800_B32","first-page":"20","article-title":"Detection of KIT mutations in core binding factor acute myeloid leukemia","volume":"10","author":"Badr","year":"2018","journal-title":"Leuk Res Rep"},{"issue":"1","key":"2021051815330396800_B33","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1182\/bloodadvances.2019000709","article-title":"Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11","volume":"4","author":"Ishikawa","year":"2020","journal-title":"Blood Adv"},{"issue":"10","key":"2021051815330396800_B34","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.leukres.2011.06.003","article-title":"Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia","volume":"35","author":"Park","year":"2011","journal-title":"Leuk Res"},{"issue":"10","key":"2021051815330396800_B35","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s00277-017-3074-y","article-title":"D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations","volume":"96","author":"Yui","year":"2017","journal-title":"Ann Hematol"},{"issue":"1","key":"2021051815330396800_B36","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.clml.2017.09.017","article-title":"Outcomes of patients with relapsed core binding factor-positive acute myeloid leukemia","volume":"18","author":"Khan","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"2021051815330396800_B37","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/ajh.23461","article-title":"Old and new prognostic factors in acute myeloid leukemia with deranged core-binding factor beta","volume":"88","author":"Cairoli","year":"2013","journal-title":"Am J Hematol"},{"issue":"10","key":"2021051815330396800_B38","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.3324\/haematol.2012.078030","article-title":"Prognosis of patients with core binding factor acute myeloid leukemia after first relapse","volume":"98","author":"Kurosawa","year":"2013","journal-title":"Haematologica"},{"issue":"2","key":"2021051815330396800_B39","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/ejh.13089","article-title":"Prognostic markers in core-binding factor AML and improved survival with multiple consolidation cycles of intermediate-\/high-dose cytarabine","volume":"101","author":"Prabahran","year":"2018","journal-title":"Eur J Haematol"},{"issue":"5","key":"2021051815330396800_B40","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s00277-019-03624-y","article-title":"Different prognostic effects of core-binding factor positive AML with Korean AML registry data","volume":"98","author":"Shin","year":"2019","journal-title":"Ann Hematol"},{"issue":"14","key":"2021051815330396800_B41","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1182\/blood-2012-06-435669","article-title":"Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial","volume":"120","author":"Yin","year":"2012","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/10\/2481\/1807519\/advancesadv2020003605.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/10\/2481\/1807519\/advancesadv2020003605.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T15:33:46Z","timestamp":1621352026000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/10\/2481\/475964\/Secondary-cytogenetic-abnormalities-in-core"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,18]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,5,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020003605","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,18]]}}}